This review article examines the safety and implications of testosterone therapy (TT) in men with testosterone deficiency (TD) who are under active surveillance or have undergone definitive treatment for prostate cancer (PCa). Emerging evidence suggests that TT does not increase the risk of developing or worsening PCa, challenging the long-held
